Ironwood Pharmaceuticals (IRWD) Non Operating Income (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Non Operating Income across 17 years of filings, most recently posting -$7.4 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at -$7.4 million, down 20102.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$28.7 million (down 31.55% YoY), and the FY2025 annual result was $193000.0, up 100.69% from the prior year.
• Non Operating Income came in at -$7.4 million for Q1 2026 at Ironwood Pharmaceuticals, down from -$6.4 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $6.9 million in Q2 2023 to a low of -$8.3 million in Q3 2024.
• The 5-year median for Non Operating Income is -$6.1 million (2024), against an average of -$3.4 million.
• Across the five-year window, Non Operating Income surged 517.38% in 2023 and slumped 20102.7% in 2026, its largest moves.
• Ironwood Pharmaceuticals' Non Operating Income stood at $3.9 million in 2022, then tumbled by 285.26% to -$7.2 million in 2023, then slipped by 3.69% to -$7.5 million in 2024, then advanced by 15.29% to -$6.4 million in 2025, then dropped by 16.55% to -$7.4 million in 2026.
• The last three Non Operating Income figures came in at -$7.4 million (Q1 2026), -$6.4 million (Q4 2025), and -$7.5 million (Q3 2025), per Business Quant data.